Efficacy News and Research

RSS

Kessler Foundation receives grants from NJ Commission to study deficits in TBI patients

The New Jersey Commission on Brain Injury Research awarded two grants to scientists at Kessler Foundation to study emotional processing deficits in people with traumatic brain injury (TBI) and the effects of aerobic exercise on memory impairments after TBI. The grants exceeded $500,000.

11 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Large study of deep brain stimulation underway for Alzheimer's disease treatment

Together, Butler Hospital and Rhode Island Hospital are participating in The ADvance Study, a clinical trial investigating the use of deep brain stimulation as a treatment for patients with Alzheimer's disease.

10 Jun 2013

Study shows Atkins diet is effective for long-term weight loss

A meta-analysis released in the June issue of the British Journal of Nutrition shows that a carbohydrate-managed approach, such as the Atkins Diet, is more effective for long-term weight loss than a conventional low-fat diet.1

7 Jun 2013

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.

7 Jun 2013

ZOLL Autopulse improves ROSC after sudden cardiac arrest

ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that a paper just published in Critical Care Medicine reported the likelihood of achieving a return of spontaneous circulation (ROSC) after sudden cardiac arrest (SCA) is 62% greater when the AutoPulse® Non-invasive Cardiac Support Pump is used to deliver CPR chest compressions.

7 Jun 2013

New technique for developing complex protein drugs from bacteria

A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield.

6 Jun 2013

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Anthrax vaccines have a prominent place in the history of medicine. This goes back to, Pasteur, who while everybody associates with the milk treatment process, also worked on rabies and Anthrax vaccines in cattle.

6 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal study of the Efficacy and Safety of Tasimelteon to treat Non-24-Hour Disorder) Phase III studies of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in totally blind individuals.

6 Jun 2013

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is initiating a multi-center clinical trial of its Symphony CGM System to support a CE Mark Technical File for marketing approval in Europe.

5 Jun 2013

Bioengineers find innovative ways to grow new cartilage from patient's own stem cells

Cartilage injuries are difficult to repair. Current surgical options generally involve taking a piece from another part of the injured joint and patching over the damaged area, but this approach involves damaging healthy cartilage, and a person's cartilage may still deteriorate with age.

5 Jun 2013

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients.

5 Jun 2013

Zalicus advancing Z944 into further clinical development

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it is advancing Z944, its novel oral T-type calcium channel blocker, into further clinical development in the third quarter of 2013.

4 Jun 2013

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

PROLOR Biotech, Inc., a company developing next-generation biobetter therapeutic proteins, today announced the initiation of a pivotal Phase III clinical trial of hGH-CTP, the company's proprietary version of human growth hormone, in growth hormone deficient adults.

4 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

Study examines link between IL-17F and treatment response to interferon beta-1b in multiple sclerosis patients

A study by Hans-Peter Hartung, M.D., of Heinrich-Heine-Universität, Düsseldoft, Germany, and colleagues examines the association between IL-17F and treatment response to interferon beta-1b among patients with relapsing-remitting multiple sclerosis.

4 Jun 2013

Study shows GreenLight laser therapy effective for BPH treatment

Data presented at the American Urological Association Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate, results in significantly shorter hospitalization, catheterization, and recovery times for patients, while maintaining equivalent safety and efficacy.

4 Jun 2013

Study examines efficacy of dietary flaxseed supplementation in management of hypercholesterolemia in children

A study by Helen Wong, R.D., of The Hospital for Sick Children, Ontario, Canada, and colleagues examined the safety and efficacy of dietary flaxseed supplementation in the management of hypercholesterolemia (high levels of cholesterol) in children.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

Efficacy News and Research

Kessler Foundation receives grants from NJ Commission to study deficits in TBI patients

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Large study of deep brain stimulation underway for Alzheimer's disease treatment

Study shows Atkins diet is effective for long-term weight loss

Ingenol mebutate drug does not offer added benefit over diclofenac/hyaluronic acid gel

ZOLL Autopulse improves ROSC after sudden cardiac arrest

New technique for developing complex protein drugs from bacteria

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Bioengineers find innovative ways to grow new cartilage from patient's own stem cells

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

Zalicus advancing Z944 into further clinical development

PROLOR Biotech announces initiation of hGH-CTP Phase III trial in growth hormone deficient adults

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Study examines link between IL-17F and treatment response to interferon beta-1b in multiple sclerosis patients

Study shows GreenLight laser therapy effective for BPH treatment

Study examines efficacy of dietary flaxseed supplementation in management of hypercholesterolemia in children

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News